- Study: Participation in diabetes education associated with greater ability to self-manage
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Hamacher's Dave Wendland to moderate DSN Diabetes & Chronic Care Roundtable for 10th-consecutive year
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- ADA issues new diet recommendations for diabetes patients
SAN DIEGO — New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.
Boehringer Ingelheim and Eli Lilly presented data from the study of Tradjenta (linagliptin) at the American Diabetes Association’s 71st Scientific Sessions in San Diego last weekend. The study showed reductions in blood sugar and weight, and a low incidence of abnormally low blood sugar, known as hypoglycemia.
The FDA approved Tradjenta as a treatment for Type 2 diabetes in May.